Method and kit for locating hyperactive parathyroid tissue or adenomatious tissue in a patient and for removal of such tissue
First Claim
1. A method for performing a parathyroidectomy in a patient to remove a parathyroid adenoma, the method comprising:
- intravenously injecting 99mTc Sestamibi into the patient;
surgically opening an operative field in the proximity of the parathyroid adenoma;
introducing into the operative field during a time window of from 2 to 2.5 hours after administering the 99mTc Sestamibi, a gamma-detecting probe to determine the location of the parathyroid adenoma upon moving the probe within the operative field; and
excising tissue identified as parathyroid adenoma.
1 Assignment
0 Petitions
Accused Products
Abstract
Disclosed herein are methods for locating hyperactive parathyroid tissue in a patient. The methods comprise providing a radiopharmaceutical which produces during a time window after administration of the radiopharmaceutical to the patient, a detectably greater radioactivity in the hyperactive parathyroid tissue than in adjacent thyroid tissue in the patient; administering the radiopharmaceutical to the patient; surgically opening an operative field in the proximity of the hyperactive parathyroid tissue; and introducing into the operative field during the time window, a probe, which detects the radioactivity produced by the hyperactive parathyroid tissue to determine the location of the hyperactive parathyroid tissue upon moving the probe within the operative field. The method is particularly applicable to radioguided parathyroidectomy using a 99mTc Sestamibi and a hand-held gamma detection probe. The gamma detection probe is also used to verify ex vivo that the resected tissue is parathyroid adenoma. Also provided are kits comprising a probe capable of detecting the radioactivity emitted from the hyperactive parathyroid tissue packaged with an instruction manual for use of the probe in performing a parathyroidectomy using 99mTc Sestamibi.
-
Citations
37 Claims
-
1. A method for performing a parathyroidectomy in a patient to remove a parathyroid adenoma, the method comprising:
- intravenously injecting 99mTc Sestamibi into the patient;
surgically opening an operative field in the proximity of the parathyroid adenoma;
introducing into the operative field during a time window of from 2 to 2.5 hours after administering the 99mTc Sestamibi, a gamma-detecting probe to determine the location of the parathyroid adenoma upon moving the probe within the operative field; and
excising tissue identified as parathyroid adenoma. - View Dependent Claims (2)
- intravenously injecting 99mTc Sestamibi into the patient;
-
3. A method for performing a parathyroidectomy in a patient to remove a parathyroid adenoma, the method comprising:
- intravenously injecting 99mTc Sestamibi into the patient;
selecting a time window of from about 1.5 to about 3.0 hours after injecting the 99mTc Sestamibi;
surgically opening an operative field in the proximity of the hyperactive parathyroid tissue during the time window;
introducing into the operative field during the time window, a gamma-detecting probe to determine the location of parathyroid adenoma upon moving the probe within the operative field; and
excising tissue identified as parathyroid adenoma. - View Dependent Claims (4)
- intravenously injecting 99mTc Sestamibi into the patient;
-
5. A method for locating hyperactive parathyroid tissue in a patient, the method comprising:
- providing a radiopharmaceutical which produces during a time window after administration of the radiopharmaceutical to the patient, a detectably greater radioactivity in the hyperactive parathyroid tissue than in adjacent thyroid tissue in the patient;
administering the radiopharmaceutical to the patient;
surgically opening an operative field in the proximity of the hyperactive parathyroid tissue; and
introducing into the operative field during the time window, a probe, which detects the radioactivity localized to the hyperactive parathyroid tissue to determine the location of the hyperactive parathyroid tissue upon moving the probe within the operative field. - View Dependent Claims (6, 7, 8, 9, 10, 11, 12, 13, 14, 15)
- providing a radiopharmaceutical which produces during a time window after administration of the radiopharmaceutical to the patient, a detectably greater radioactivity in the hyperactive parathyroid tissue than in adjacent thyroid tissue in the patient;
-
16. A method for locating hyperactive parathyroid tissue in a patient comprising:
- selecting a time window during which the hyperactive parathyroid tissue has detectably greater radioactivity than adjacent thyroid tissue in the patient following administration of a radiopharmaceutical;
administering the radiopharmaceutical to the patient;
surgically opening an operative field in the proximity of the hyperactive parathyroid tissue; and
introducing into the operative field during the time window, a probe which detects the radioactivity localized in the hyperactive parathyroid tissue to determine the location of hyperactive parathyroid tissue upon moving the probe within the operative field. - View Dependent Claims (17, 18, 19, 20, 21, 22, 23, 24, 25, 26)
- selecting a time window during which the hyperactive parathyroid tissue has detectably greater radioactivity than adjacent thyroid tissue in the patient following administration of a radiopharmaceutical;
-
27. A kit comprising a probe capable of detecting radioactivity packaged with a manual providing instructions for use of the probe for locating hyperactive parathyroid tissue following administration of a radiopharmaceutical which produces a detectably greater radioactivity in the hyperactive parathyroid tissue than adjacent thyroid tissue, by introducing into a surgically opened operative field in the proximity of the hyperactive parathyroid tissue the probe which detects the radioactivity produced by the hyperactive parathyroid tissue.
-
28. A method for distinguishing an adenoma from adjacent non-adenomatous tissue in a re-operative surgical field, the method comprising:
- administering to the patient a radiopharmaceutical which produces a detectably greater radioactivity in the adenoma than in adjacent non-adenomatous tissue in the patient;
surgically opening the re-operative field and introducing into the re-operative field a gamma probe to detect the radioactivity produced by the adenoma and determine the location of the adenoma upon moving the gamma probe within the re-operative field.
- administering to the patient a radiopharmaceutical which produces a detectably greater radioactivity in the adenoma than in adjacent non-adenomatous tissue in the patient;
-
29. A method for locating a parathyroid adenoma positioned in the chest of a patient, from adjacent non-adenomatous tissue, the method comprising:
- administering to the patient a radiopharmaceutical which produces a detectably greater radioactivity in the parathyroid adenoma than in the adjacent non-adenomatous tissue in the patient;
surgically opening an operative field in the proximity of the parathyroid adenoma via an incision between two ribs or through the bed of a resected rib segment of the patient; and
introducing into the operative field a probe adapted for insertion into the operative field wherein the probe detects the radioactivity produced by the parathyroid adenoma top determine the location of the parathyroid adenoma upon movement of the probe within the operative field. - View Dependent Claims (30, 31, 32, 33, 34, 35, 36, 37)
- administering to the patient a radiopharmaceutical which produces a detectably greater radioactivity in the parathyroid adenoma than in the adjacent non-adenomatous tissue in the patient;
Specification